Administration of recombinant E. coli-expressed human AIMp1 protein to tumor-bearing mice has been shown to have tumor inhibitory effects in a human xenograft model of stomach cancer (38, 39) as well as EG7 lymphoma (40), breast cancer (41), and others. Here, AIMP1 is linked to gastric cancer.